throbber
UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`Filed: April 19, 2017
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`MYLAN PHARMACEUTICALS INC., ACTAVIS
`LABORATORIES FL, INC., AMNEAL PHARMACEUTICALS LLC,
`AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY'S
`LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD.,
`SUN PHARMACEUTICALS INDUSTRIES, LTD.,
`SUN PHARMACEUTICALS INDUSTRIES, INC.,
`TEVA PHARMACEUTICALS USA, INC., WEST-WARD
`PHARMACEUTICAL CORP., and HIKMA PHARMACEUTICALS, LLC,
`
`Petitioners
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`
`Patent Owner
`
`Case IPR2016-013321
`Patent 8,822,438 B2
`
`
`
`
`
`THIRD UPDATED LIST OF PETITIONER’S EXHIBITS
`
`
`
`
` 1
`
` Case IPR2017-00853 has been joined with this proceeding.
`
`
`
`

`

`Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits the following current
`
`exhibit list.
`
`Exhibit
`
`MYL 1001
`
`MYL 1002
`
`MYL 1003
`
`MYL 1004
`
`MYL 1005
`
`Description
`U.S. Patent No. 8,822,438, Auerbach and Belldegrun, “Methods
`and Compositions for Treating Cancer” (“the ’438 patent”)
`Declaration of Marc B. Garnick, MD (“Garnick Decl.”)
`O’Donnell, A. et al., “Hormonal impact of the 17α-
`hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630)
`in patients with prostate cancer,” Br. J. Cancer, (90):2317–2325
`(2004) (“O’Donnell”)
`Gerber, G.S. et al., “Prostate specific antigen for assessing
`response to ketoconazole and prednisone in patients with hormone
`refractory metastatic cancer,” J. Urology, 144(5):1177–9 (1990)
`(“Gerber”)
`U.S. Patent No. 5,604,213, Barrie S.E. et al., “17-Substituted
`Steroids Useful In Cancer Treatment” (“the ’213 patent”)
`Tannock, I. et al., “Chemotherapy with mitoxantrone plus
`prednisone or prednisone alone for symptomatic hormone-
`resistant prostate cancer: a Canadian randomized trial with
`palliative end points,” J. Clinical Oncology, 14:1756–1764 (1996)
`(“Tannock”)
`February 3, 2012 Office Action (excerpt from prosecution history
`of ’438 patent)
`July 3, 2012 Response (excerpt from prosecution history of ’438
`patent)
`Ryan, C.J. et al., “Abiraterone in metastatic prostate cancer
`without previous chemotherapy,” New Eng. J. Med., 368:138–148
`(2013).
`January 11, 2013 Response (excerpt from prosecution history of
`’438 patent)
`MYL 1011 March 4, 2013 Office Action (excerpt from prosecution history of
`’438 patent)
`
`MYL 1006
`
`MYL 1007
`
`MYL 1008
`
`MYL 1009
`
`MYL 1010
`
`
`
`2
`
`

`

`Exhibit
`
`MYL 1012
`
`MYL 1013
`
`MYL 1014
`
`MYL 1015
`
`MYL 1016
`
`MYL 1017
`
`MYL 1018
`
`MYL 1019
`
`MYL 1020
`
`MYL 1021
`
`MYL 1022
`
`MYL 1023
`
`MYL 1024
`
`Description
`June 4, 2013 Response (excerpt from prosecution history of ’438
`patent)
`July 3, 2013 Notice of Allowance (excerpt from prosecution
`history of ’438 patent)
`October 25, 2013 Notice of Allowance (excerpt from prosecution
`history of ’438 patent)
`February 11, 2014 Notice of Allowance (excerpt from prosecution
`history of ’438 patent)
`June 2, 2014 Notice of Allowance (excerpt from prosecution
`history of ’438 patent)
`Confidential Declaration of Ivan T. Hofmann (“Hofmann
`Declaration”)
`2011 Zytiga® Approval Prescribing Information
`2015 Zytiga® Prescribing Information, Co-administration
`Brochure
`Harris, K.A. et al., “Low dose ketoconazole with replacement
`doses of hydrocortisone in patients with progressive androgen
`independent prostate cancer,” J. Urology, 168:542–545 (August
`2002)
`Oh, W.K. “Secondary hormonal therapies in the treatment of
`prostate cancer,” Urology, 60(Supp. 3A):87–93 (2002)
`Tannock, I. et al., “Docetaxel plus prednisone or mitoxantrone
`plus prednisone for advanced prostate cancer,” N. Eng. J. Med.,
`351:1502–12 (2004)
`Attard, G. et al., “Selective blockade of androgenic steroid
`synthesis by novel lyase inhibitors as a therapeutic strategy for
`treating metastatic prostate cancer,” Br. J. Urol., 96(9): 1241–
`1246 (2005)
`Hellerstedt, B.A. et al., “The current state of hormonal therapy for
`prostate cancer,” CA Cancer J. Clin., 52:154–179 (2002).
`
`
`
`3
`
`

`

`Exhibit
`
`MYL 1025
`
`MYL 1026
`
`MYL 1027
`
`MYL 1028
`
`MYL 1029
`
`MYL 1030
`
`MYL 1031
`
`MYL 1032
`
`MYL 1033
`
`MYL 1034
`
`MYL 1035
`
`MYL 1036
`
`MYL 1037
`
`Description
`Kasper, D.L. et al. (Eds.), Harrison’s Principles of Internal
`Medicine, 16th Edition (2005), 549.
`Auchus, R.J. “The genetics, pathophysiology, and management of
`human deficiencies of P450c17,” Endocrinol. Metab. Clin. North
`Am. 30(1):101–119 (2001)
`Costa-Santos, M. et al., “Two prevalent CYP17 mutations and
`genotype-phenotype correlations in 24 Brazilian patients with 17-
`hydroxylase deficiency,” J. Clin. Endocrin. & Metabol., 89(1):49–
`60 (2004)
`Jubelirer, S.J., et al., “High dose ketoconazole for the treatment of
`hormone refractory metastatic prostate carcinoma,” J. Urol.,
`142(1):89–91 (1989)
`U.S. Patent 5,688,977, Sisti, N.J. et al., “Method for Docetaxel
`Synthesis”
`U.S. Food and Drug Administration (“FDA”) FDA News Release
`dated May 19, 2004, “FDA Approves New Indication for
`Taxotere-Prostate Cancer”
`Tannock, I. et al., “Treatment of metastatic prostatic cancer with
`low-dose prednisone: evaluation of pain and quality of life as
`pragmatic indices of response,” J. Clin. Oncology, 7:590–7 (1989)
`Intentionally left blank
`Scher, H.I. et al., “Increased survival with enzalutamide in
`prostate cancer after chemotherapy,” New Eng. J. Med.,
`367:1187–97 (2012)
`de Bono, J.S. et al., “Abiraterone and increased survival in
`metastatic prostate cancer,” New Engl. J. Med., 364:1995–2005
`(2011)
`Orange Book listing for Zytiga®
`Initial Application (excerpt from prosecution history of ’438
`patent)
`Intentionally left blank
`
`
`
`4
`
`

`

`Exhibit
`MYL 1038
`
`MYL 1039
`
`MYL 1040
`
`MYL 1041
`
`MYL 1042
`MYL 1043
`MYL 1044
`
`MYL 1045
`
`MYL 1046
`
`MYL 1047
`
`MYL 1048
`
`MYL 1049
`
`Description
`
`Intentionally left blank
`September 11, 2012 Office Action (excerpt from prosecution
`history of ’438 patent)
`Cancer.net (ASCO Patient Website), Treatment of Metastatic
`Castration-Resistant Prostate Cancer,
`http://www.cancer.net/research-and-advocacy/asco-care-and-
`treatment-recommendations-patients/treatment-metastatic-
`castration-resistant-prostate-cancer (accessed 6/28/2016).
`Cancer.org (ACS), “What are the key statistics about prostate
`cancer?”
`http://www.cancer.org/cancer/prostatecancer/detailedguide/prostat
`e-cancer-key-statistics (accessed 6/28/2016).
`Intentionally left blank
`Intentionally left blank
`Intentionally left blank
`FDA News Release, “FDA expands Zytiga’s use for late-stage
`prostate cancer,” 12/10/2012
`http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncement
`s/ucm331492.htm (access 6/30/2016).
`FDA Website, Drugs@FDA – Zytiga,
`http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?
`fuseaction=Search.DrugDetails (accessed 6/28/2016).
`FDA Website, Orange Book, Zytiga (NDA 202379),
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cf
`m?Appl_No=202379&Product_No=001&table1=OB_Rx
`(accessed 6/30/2016).
`Galderma Labs., L.P. v. Tolmar, Inc., 737 F.3d 731, 740–41 (Fed.
`Cir. 2013).
`Jevtana Website, Dosing and Administration,
`http://www.jevtana.com/hcp/dosing/default.aspx (accessed
`6/28/2016).
`
`
`
`5
`
`

`

`Exhibit
`
`MYL 1050
`
`MYL 1051
`
`Description
`Kirby, M. et al., “Characterising the castration-resistant prostate
`cancer population: A systematic review,” Int’l J. Clinical Practice,
`65(11):1180–1192 (2011).
`Mayo Clinic Website, Prostate cancer,
`http://www.mayoclinic.org/diseasesconditions/prostate-
`cancer/basics/definition/con-20029597?p=1 (accessed 6/28/2016).
`Intentionally left blank
`MYL 1052
`MYL 1053 Merck & Co. v. Teva Pharms. USA, Inc., 395 F.3d 1364 (Fed. Cir.
`2005).
`Murphy, W.J., J.L. Orcutt & P.C. Remus (2012), Patent
`Valuation: Improving Decision Making through Analysis,
`Hoboken, NJ: Wiley.
`PMLiVe Website, “Top 50 Pharmaceutical Products by Global
`Sales,”
`http://www.pmlive.com/top_pharma_list/Top_50_pharmaceutical
`_products_by_global_sales (accessed 6/30/2016).
`Intentionally left blank
`Syntex (U.S.A.) LLC v. Apotex, Inc., 407 F.3d 1371 (Fed. Cir.
`2005).
`
`MYL 1054
`
`MYL 1055
`
`MYL 1056
`
`MYL 1057
`
`MYL 1058-
`MYL 1063
`MYL 1064
`MYL 1065
`
`MYL 1066
`
`MYL 1067
`
`MYL 1068
`
`MYL 1069
`
`
`
`Intentionally left blank
`
`Zytiga Brochure, Putting Prednisone in Perspective, 3/2015.
`Zytiga Label, 5/20/2015.
`Zytiga Website, How Zytiga® (abiraterone acetate) Works,
`https://www.zytiga.com/print/about-zytiga/how-zytiga-works
`(accessed 6/28/2016).
`Intentionally left blank
`November 25, 2011 Office Action (excerpt from prosecution
`history of ’438 patent)
`December 21, 2011 Response (excerpt from prosecution history
`of ’438 patent)
`
`6
`
`

`

`Exhibit
`
`MYL 1070
`
`MYL 1071
`
`MYL 1072
`
`MYL 1073
`
`MYL 1078
`
`Description
`September 11, 2012 Office Action (excerpt from prosecution
`history of ’438 patent)
`October 3, 2013 IDS (excerpt from prosecution history of ’438
`patent)
`October 3, 2013 IDS (excerpt from prosecution history of ’438
`patent)
`January 10, 2014 IDS (excerpt from prosecution history of ’438
`patent)
`MYL 1074 May 9, 2014 IDS (excerpt from prosecution history of ’438
`patent)
`MYL 1075 May 9, 2014 IDS (excerpt from prosecution history of ’438
`patent)
`MYL 1076 May 30, 2014 IDS (excerpt from prosecution history of ’438
`patent)
`MYL 1077 May 30, 2014 IDS (excerpt from prosecution history of ’438
`patent)
`Barrie et al., “Pharmacology of novel steroidal inhibitors of
`Cytochrome P45017α (17α-hydroxylase/C17,20 lyase),”
`J. Steroid Biochem. Molec. Biol., 50:267-73 (1994)
`Fakih, M. et al., “Glucocorticoids and treatment of prostate
`cancer: A preclinical and clinical review,” Urology, 60:553-561
`(2002)
`Lam, J.S. et al., “Secondary hormonal therapy for advanced
`prostate cancer,” J. Urology, 175:28-34 (2006)
`Declaration of Bryan D. Beel in Support of Motion for Pro Hac
`Vice Admission
`Intentionally Left Blank
`Intentionally Left Blank
`Declaration of Shannon M. Bloodworth in Support of Motion for
`Pro Hac Vice Admission
`
`MYL 1079
`
`MYL 1080
`
`MYL 1081
`
`MYL 1082
`MYL 1083
`
`MYL 1084
`
`
`
`7
`
`

`

`Exhibit
`
`MYL 1085
`
`MYL 1086
`
`MYL 1087
`
`MYL 1088
`
`MYL 1089
`
`MYL 1090
`MYL 1091
`
`MYL 1092
`
`MYL 1093
`
`MYL 1094
`
`MYL 1095
`
`Description
`Potter, G.A. et al., “Novel steroidal inhibitors of human
`cytochrome P45017 (17-hydroxylase-C17,20-lyase): potential
`agents for the treatment of prostatic cancer,” J. Med. Chem.,
`38:2463-2471 (1995)
`Attard, G. et al., “Clinical and biochemical consequences of
`CYP17A1 inhibition with abiraterone given with and without
`exogenous glucocorticoids in castrate men with advanced prostate
`cancer,” J. Clin. Endocrinol. Metab., 97:507-516 (2012)
`Declaration of Robert D. Swanson in Support of Motion for Pro
`Hac Vice Admission
`BTG Press Release, “BTG licenses new prostate cancer drug to
`Cougar Biotechnology,” 4/20/2004
`http://www.btgplc.com/media/press-releases/btg-licenses-new-
`prostate-cancer-drug-to-cougar-biotechnology (accessed
`4/3/2017)
`Zytiga Website, About Zytiga® (abiraterone acetate),
`https://www.zytiga.com/choosing-zytiga/results-of-zytiga
`(accessed 4/3/2017)
`Patent Owner’s Response, Paper No. 35 (Mar. 8, 2017)
`Reply Declaration of Ian McKeague, Ph.D.
`Cancer.org (ACS), “Hormone therapy for prostate cancer,”
`https://www.cancer.org/conten/cancer/en/cancer/prostate-
`cancer/treating/hormone-therapy.html (accessed 4/10/2017)
`Cancer.gov (NIH NCI), “Metastatic cancer,”
`https://www.cancer.gov/types/metastatic-cancer.html (accessed
`4/14/2017)
`Canger.gov (NIH NCI), “Prostate-specific antigen (PSA) test,”
`https://www.cancer.gov/types/prostate/psa-fact-sheet (accessed
`4/11/2017)
`Cougar Biotechnology, Inc., Clinical Study Report: COU-AA-001
`and COU-AA-001 EXT (Nov. 17, 2010)
`
`
`
`8
`
`

`

`Exhibit
`
`MYL 1096
`
`MYL 1097
`
`MYL 1098
`
`MYL 1099
`
`MYL 1100
`
`MYL 1101
`
`MYL 1102
`
`MYL 1103
`
`MYL 1104
`
`MYL 1105
`
`Description
`Reid, A.H.M. et al., “Significant and sustained antitumor activity
`in post-docetaxel, castration-resistant prostate cancer with the
`CYP17 inhibitor abiraterone acetate,” J. Clin. Onc., 28(9):1489-
`1495 (2010)
`Reply Declaration of John Bantle, M.D.
`Arlt, W. et al., “Adrenal insufficiency,” Lancet, 361:1881-93
`(2003)
`Oelkers, W., “Dose-response aspects in the clinical assessment of
`the hypothalamo-pituitary-adrenal axis, and the low-dose
`adrenocorticotropin test,” Eur. J. Endocrin., 135:27-33 (1996)
`Fosså, S.D. et al., “Flutamide versus prednisone in patients with
`prostate cancer symptomatically progressing after androgen-
`ablative therapy: A phase III study of the European Organization
`for Research and Treatment of Cancer Genitourinary Group,” J.
`Clin. Oncol., 19:62-71 (2001)
`Osoba, D. et al., “Health-related quality of life in men with
`metastatic prostate cancer treated with prednisone alone or
`mitoxantrone and prednisone,” J. Clin. Oncol., 17(6):1654-63
`(1999)
`Auchus, R.J. et al., “Use of prednisone with abiraterone acetate in
`metastatic castration-resistant prostate cancer,” Oncologist,
`19:1231-1240 (2014)
`Luthy, I.A. et al., “Androgenic activity of synthetic progestins and
`spironolactone in androgen-sensitive mouse mammary carcinoma
`(shionogi) cells in culture,” J. Steroid Biochem., 31(5):845-852
`(1988)
`Reply Declaration of Marc B. Garnick, M.D.
`Marc B. Garnick, Management of Metastatic Carcinoma of the
`Prostate – Treatment Options and Controversies, in PROSTATIC
`DISORDERS 354-67 (David F. Paulson et al. eds., 1989)
`
`
`
`9
`
`

`

`Exhibit
`
`MYL 1106
`
`MYL 1107
`
`MYL 1108
`
`MYL 1109
`
`MYL 1110
`
`MYL 1111
`
`MYL 1112
`
`MYL 1113
`
`MYL 1114
`
`Description
`De Coster, R. et al., “Effects of high-dose ketoconazole and
`dexamethasone on ACTH-stimulated adrenal steroidogenesis in
`orchiectomized prostatic cancer patients,” Acta Endocrinologica,
`115:265-271 (1987)
`Trump, D. L. et al., “High-dose ketoconazole in advanced
`hormone-refractory prostate cancer: endocrinologic and clinical
`effects,” J. Clin. Oncol., 7:1093-98 (1989)
`Figg, W.D. et al., “A randomized, phase II trial of ketoconazole
`plus alendronate versus ketoconazole alone in patients with
`androgen independent prostate cancer and bone metastases,” J.
`Urol., 173:790-96 (2005)
`Chang, A.Y.C. et al., “A study of aminoglutethemide and
`hydrocortisone in patients with advanced and refractory prostate
`carcinoma,” Am. J. Clin. Oncol., 12(4):358-360 (1989)
`Kruit, W.H. et al., “Effect of combination therapy with
`aminoglutethimide and hydrocortisone on prostate-specific
`antigen response in metastatic prostate cancer refractory to
`standard endocrine therapy,” Anit-Cancer Drugs, 15:843-47
`(2004)
`Bernard P. Schimmer and Keith L. Parker, Andrenocorticotropic
`Hormone: Adrenocortical Steroids and Their Synthetic Analogs;
`Inhibitors of the Synthesis and Actions of Adrenocortical
`Hormones, in GOODMAN & GILMAN’S THE PHARMACOLOGICAL
`BASIS OF THERAPEUTICS 1649-77 (10th ed. 2001)
`Small, E.J. et al., “Second-line hormonal therapy for advanced
`prostate cancer: A shifting paradigm,” J. Clin. Oncol., 15:382-88
`(1997)
`Small, E.J. et al., “Ketoconazole retains activity in advanced
`prostate cancer patients with progression despite flutamide
`withdrawal,” J. Urol., 157:1204-07 (1997)
`Ponder, B.A.J. et al., “Response to aminoglutethimide and
`cortisone acetate in advanced prostatic cancer,” Br. J. Cancer,
`50:757-63 (1984)
`
`
`
`10
`
`

`

`Exhibit
`
`MYL 1115
`
`MYL 1116
`
`MYL 1117
`
`MYL 1118
`
`MYL 1119
`
`MYL 1120
`
`MYL 1121
`
`MYL 1122
`
`MYL 1123
`
`Description
`Labrie, F. et al., “Anti-hormone treatment for prostate cancer
`relapsing after treatment with flutamide and castration addition
`of aminoglutethimide and low dose hydrocortisone to
`combination therapy,” Brit. J. Urol., 63:634-38 (1989)
`Berry, W. et al., “Phase III study of mitoxantrone and low dose
`prednisone versus low dose prednisone alone in patients with
`asymptomatic hormone refractory prostate cancer,” J. of Urology,
`168:2439-43 (2002)
`Abiraterone Acetate: Abbreviated Clinical Study Report Synopsis
`COU-AA-BE (Doc. EDMS-ERI-13494974:2.0) (“BE Synopsis”)
`Hugo Vanden Bossche et al., Effects of Inhibitors on the P450-
`Dependent Metabolism of Endogenous Compounds in Fungi,
`Protozoa, Plants and Vertebrates, in MOLECULAR ASPECTS OF
`MONOOXYGENASES AND BIOACTIVATION OF TOXIC COMPOUNDS
`345-63 (Emel Arinc et al. eds., 1991)
`Charles L. James et al., Antimicrobial Therapy, in TRAUMA
`CRITICAL CARE 927-60 (William C. Wilson et al. eds., 2007)
`Sartor, O. et al., “Effect of prednisone on prostate-specific
`antigen in patients with hormone-refractory prostate cancer,”
`Urology, 52:252-56 (1998)
`Collette, L. et al., “Is prostate-specific antigen a valid surrogate
`end point for survival in hormonally treated patients with
`metastatic prostate cancer? Joint research of the European
`Organisation for Research and Treatment of Cancer, the
`Limburgs Universitair Centrum, and AstraZeneca
`Pharmaceuticals,” J. Clin. Oncol., 23(25):6139-48 (2005)
`Collette, L. et al., “Prostate-specific antigen (PSA) alone is not
`an appropriate surrogate marker of long-term therapeutic benefit
`in prostate cancer trials,” Eur. J. Can., 42:1344-50 (2006)
`Halabi, S. et al., “Prostate-specific antigen changes as surrogate
`for overall survival in men with metastatic castration-resistant
`prostate cancer treated with second-line chemotherapy,” J. Clin.
`Oncol., 31(31):3944-50 (2013)
`
`
`
`11
`
`

`

`Exhibit
`
`MYL 1124
`
`MYL 1125
`MYL 1126
`MYL 1127
`MYL 1128
`MYL 1129
`MYL 1130
`MYL 1131
`MYL 1132
`
`MYL 1133
`
`MYL 1134
`MYL 1135
`MYL 1136
`
`MYL 1137
`
`MYL 1138
`MYL 1139
`MYL 1140
`
`MYL 1141
`
`Description
`Scher, H.I. et al., “Design and end points of clinical trials for
`patients with progressive prostate cancer and castrate levels of
`testosterone: recommendations of the Prostate Cancer Clinical
`Trials Working Group,” J. Clin. Oncol., 26(7):1148-59 (2008)
`FDA, Prostate Cancer End Points Workshop (2004)
`Intentionally left blank
`Intentionally left blank
`Intentionally left blank
`FDA letter approving Taxotere (May 19, 2004)
`U.S. Patent No. 7,709,517
`U.S. Patent No. 8,183,274
`U.S. Patent No. 9,126,941
`Orange Book, “Xtandi,”
`https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?
`Product_No=001&Appl_No=203415&Appl_type=N.html
`Confidential Reply Declaration of Ivan T. Hofmann
`Deposition of Matthew Rettig, M.D. (Mar. 31, 2017)
`Deposition of Christopher Vellturo, Ph.D. (Apr. 5, 2017)
`Deposition of Christopher Vellturo, Ph.D., Amerigen Pharms. Ltd.
`v. Janssen Oncology, Inc., IPR No. 2016-00286 (Dec. 20, 2016)
`Jevtana prescribing information (Sept. 2016)
`Taxotere prescribing information (Dec. 2015)
`Taxotere label (May 2004)
`Johnson & Johnson Press Release, “Zytiga® approved in the EU
`for use in the treatment of metastatic castration-resistant prostate
`cancer before chemotherapy,” 1/11/2013
`http://www.jnj.com/media-center/press-releases/zytiga-approved-
`in-the-eu-for-use-in-the-treatment-of-metastatic-castration-
`resistant-prostate-cancer-before-chemotherapy
`
`
`
`12
`
`

`

`Exhibit
`MYL 1142
`MYL 1143
`MYL 1144
`MYL 1145
`
`Description
`Deposition of Ian Judson (Apr. 7, 2017)
`Confidential Deposition of Richard Auchus (Apr. 10, 2017)
`Non-Confidential Deposition of Richard Auchus (Apr. 10, 2017)
`Non-Confidential Reply Declaration of Ivan T. Hofmann
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`Reg. No. 52,354
`
`PERKINS COIE LLP
`700 13th Street, NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6204
`Facsimile: (202) 654-6211
`Email: bmwhite@perkinscoie.com
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`
`
`
`
`
`
`Dated: April 19, 2017
`
`
`
`13
`
`

`

`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing Third Updated List of
`
`Petitioner’s Exhibits was served electronically via email as follows:
`
`Patent Owners:
`
`Patent Owners:
`
`Dianne B. Elderkin
`Barbara L. Mullin
`Ruben H. Munoz
`Akin Gump Strauss Hauer & Feld LLP
`JANS-ZYTIGA@akingump.com
`
`Todd L. Krause
`David T. Pritikin
`Bindu Donovan
`Paul J. Zegger
`Sidley Austin LLP
`ZytigaIPRTeam@sidley.com
`
`
`
`Petitioners:
`
`Samuel S. Park
`Jovial Wong
`Ryan B. Hauer
`Winston & Strawn LLP
`spark@winston.com
`jwong@winston.com
`rhauer@winston.com
`
`
`
`
`
`
`Dated: April 19, 2017
`
`
`
`/Brandon M. White/
`Brandon M. White
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`
`
`
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket